Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.

Jian Li, Lin Shen, Jieer Ying et al.|Journal of Clinical Oncology|2022

Cited by 2